Key Takeaways
- Recovery taking shape, but FY26 was a reset year: Revenue of INR1,713 crores with EBITDA margins at 12.9% reflects a year of remediation, with Q4 showing sequential strengthening to 20.3% margins on INR519 crores revenue.
- FDA warning letter is the central drag on pharma: The Bangalore site issue slowed Q4 shipments and will mute new CDMO growth until resolved; management targets resolution by end of this year.
- Crop Protection has likely bottomed: Q4 delivered a recovery driven by volume offtake normalization, and management believes the industry has moved beyond the worst phase of the inventory correction cycle.
- Animal Health CDMO is a bright spot: All products from the global multinational contract are now in commercial phase, and the business remains on track toward the INR500 crores plus ambition over 4–5 years.
- What to watch next quarter: Whether the FDA inspection timeline firms up, the pace of pharma volume recovery, and how much of the raw material cost spike flows through before pass-through mechanisms kick in.
The FDA Overhang: Bangalore Warning Letter
- What happened: The U.S. FDA warning letter at the Bangalore site forced the company to slow production and pressure-test systems on GMP consultant advice. No customers were lost, but price releases and shipments of own products were delayed in Q4, and new CDMO NCEs with multi-source options saw volumes split across suppliers.
- The growth that vanished: Management stated that without the FDA issue, the pharma business would have shown growth in FY26; instead, H1 was soft and H2 delivered only a partial recovery.
- Remediation status: All CAPAs are nearing completion, and an FDA inspection is expected toward the end of this year, with resolution hoped for in the next few quarters.
- Mitigation in motion: A new pilot plant in Panoli (an FDA-approved site with no warning issue) has been commercialized and is being used to derisk Bangalore; 5 to 6 new DMF filings have already been done from Panoli.
- The CDMO constraint: Till the FDA matter is resolved, new NCE growth will remain muted because innovators with optionality split volumes; existing CDMO business is intact and continues.
Hiremath: "We are going through this bit of an aberration, a dip. I think it's now getting behind us. In the next few quarters, we'll be out of it. And the visibility for medium to long-term revenue growth still stands."
Pharma & CDMO: The Growth Engine Under Repair
- Demand backdrop improving: Demand trends strengthened across both API and CDMO segments through the year, supported by customer ordering normalization and increased outsourcing opportunities. Capacity utilization across pharma facilities improved quarter-on-quarter.
- Strategic investments now operational: The new high-potency laboratory, expanded R&D infrastructure in Pune, and the new Panoli pilot plant have all become operational over the last 12–18 months and are beginning to strengthen the company's position in complex and differentiated chemistries.
- Utilization paradox: Utilization rose to 80–85% (from 75% last year) even as revenue declined, because post-FDA compliance, CAPA implementation, and additional checks increased batch cycle times.
- DMF filing acceleration: The company is now targeting 5 to 6 DMF filings annually, up from 2 to 3 historically, with filings already done from the Panoli site.
- Next-gen capabilities are long-dated bets: HPAPI lab work has just started, and a manufacturing facility is planned over FY28 with revenues 3–5 years out. ADC plans are limited to payload and linker synthesis only. The company is not entering steroids or hormones.
- The 5-year underperformance question: Per an analyst's math, Hikal has underperformed wider pharma CDMO peers in India by a large margin over 5 years. Management attributes this to recent setbacks, not capabilities, and notes some products became old and commoditized, so volume growth did not translate to equivalent value growth.
Crop Protection: A Cycle Turning
- Q4 recovery delivered: The segment improved both sequentially and YoY, driven by increased volume offtake from key products and gradual normalization across the global agrochemical value chain.
- Inventory correction done, pricing still weak: True demand has returned because the inventory correction is more or less complete, but pricing pressures persist because Chinese manufacturers have not raised prices; management notes the Chinese government appears to be absorbing input cost increases.
- Structural margin improvement in the pipeline: The company is actively progressing deep contract manufacturing engagements, co-development R&D projects, and long-term supply agreements with global innovators, several of which carry structurally better margins and improved long-term revenue visibility.
- New leadership and front-end build-out: Ravi Khadabadi has been appointed as the new Crop Protection Head, and the company is establishing a Brazil office with a dedicated leadership addition in Latin America.
- NCE launches ahead: New RFPs won in the last year include a few NCE products set to launch in the next financial year; pilot trials are currently ongoing.
Hiremath: "We believe the industry has now largely moved beyond the worst phase of the cycle."
Animal Health & Diversification
- CDMO validation complete, commercial phase underway: All products from the global multinational contract have been validated and are progressing well into commercial supply.
- Revenue ramp on track: Management reaffirmed the ambition to build an INR500 crores plus business in the next 4–5 years, supported by a healthy pipeline and good commercial products, with no indications of degrowth from any current portfolio products.
- Geographic expansion pending: Volumes are expected to scale progressively as approvals across several additional geographies are received over time.
- Specialty Chemicals and Personal Care: The company expects to progress in these businesses over the coming years, which will help diversify revenue streams and improve margins.
Margins & Cost Headwinds
- Q4 margin improvement: EBITDA margins improved to 20.3% in Q4 from the full-year level of 12.9%, driven by better product mix, improved utilization, and operating leverage.
- Raw material spike is a near-term risk: Solvent prices (toluene, methanol, acetone, benzene) have shot up since March to significantly elevated levels. For CDMO products, a pass-through mechanism exists but carries a lag effect of about a quarter.
- Net impact expected to be manageable: Management expects customer-supported price pass-through to partially offset increases, with no significant bottom-line impact net-net, though Q1 FY27 could see some marginal pressure from the lag.
- Impairment taken: An exceptional charge of INR47 crores was booked in Q4 for impairment of a multipurpose plant at Panoli that was retrofitted from crop protection to pharma use.
Hiremath: "net-net, we will end up ensuring that there's no significant impact on the bottom line, although for 1 or 2 quarters, especially quarter 1, there could be some marginal impact because by the time the pass-through happens and the negotiations end, there's a lag effect."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FDA resolution | Inspection expected, all CAPAs nearing completion | End of this year |
| DMF filing cadence | 5 to 6 filings annually (up from 2–3 historically) | Ongoing from FY27 |
| HPAPI manufacturing facility | Planned in Pune | Over FY28 |
| HPAPI/ADC revenue scale-up | Meaningful scale-up | 3 to 5 years |
| Animal Health revenue target | INR500 crores plus | Next 4–5 years |
| Crop Protection NCE launches | New products from RFPs won in the last year | FY27 |
| Brazil office | Establishment in progress | Not specified |
| FY27 margin outlook | Sustain at improved levels, supported by demand visibility and operating leverage | FY27 |
| Raw material pass-through | Customer-supported mechanisms to partially offset cost increases; marginal Q1 impact possible | Q1 FY27 lag, then normalize |
| FY30 strategic plan | Plans stand but delayed by 2–3 years due to recent setbacks | FY32–33 (implied) |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹519 cr, FY26 revenue ₹1,713 cr |
| EBITDA | ₹105 cr, EBITDA margin 20.3% |
| EBITDA margin | 20.3%, improved over previous quarter; FY26 margin 12.9% |
| PAT | ₹14.4 cr, after exceptional item of ₹47 cr for Panoli plant impairment |
| Pharma revenue | ₹292 cr, FY26 revenue ₹1,021 cr |
| Pharma EBIT margin | 12%, EBIT ₹35 cr; sequential operating profit up 45% |
| Crop Protection revenue | ₹228 cr, FY26 revenue ₹692 cr |
| Crop Protection EBIT margin | 17.1%, EBIT ₹39 cr |
| Pharma capacity utilization | 80% to 85%, at Panoli and Bangalore plants, up from 75% last year |
| DMF filings target | 5 to 6 annually, compared to 2 to 3 historically |
| FY26 capex | ₹149 cr, for debottlenecking, regulatory upgrades, expanding CDMO capacities |
| Debt-to-equity ratio | 0.56, reduced from 0.59 as on March 31, 2026 |
| FY26 adjusted PBT from operations | ₹7 cr, after adjusting exceptional items of ₹85 cr |
| Animal Health medium-term revenue target | ₹500 cr plus, in next 4 to 5 years, on track per September guidance |